Ecopia BioSciences Inc.

Ecopia BioSciences Inc.

March 29, 2006 16:28 ET

Ecopia Presents Data Highlighting the Potential of Decipher'R' Discovery Platform at the NCI Drug Discovery and Development Seminar Series

MONTREAL, QUEBEC--(CCNMatthews - March 29, 2006) - Ecopia BioSciences Inc. (TSX:EIA) - Dr Jim McAlpine, Vice-President, Chemistry and Discovery, made a presentation today at the National Cancer Institute (NCI) entitled "Genomics of Secondary Metabolite Biosynthesis as a Platform for Drug Discovery". This presentation was made in the context of The Drug Discovery and Development Seminar Series held in Frederick, Maryland.

Dr McAlpine talked about the unique potential of the DECIPHER® platform, Ecopia's discovery technology engineered to discover novel chemical entities such as ECO-4601, the Company's lead compound, which is being developed as a novel anticancer agent, now in Phase I of clinical development.

Ecopia's DECIPHER® platform represents 21st century know how that is applied to one of the most abundant sources of successful drugs known in modern medical history. The source is soil-dwelling microorganisms that have produced several potent anticancer agents such as doxorubicin, bleomycin and mitomycin. To date, we have isolated and produced 59 New Chemical Entities (NCE's), 14 of which have shown anticancer activities.

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to advance our flagship compound, ECO-4601, through the different stages of clinical trials. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the DECIPHER® technology. The common shares of Ecopia are listed on the TSX (symbol: EIA).

This press release may contain forward-looking statements that reflect the Company's current expectations regarding future events. The forward-looking statements, including expectations as to the pharmaceutical potential of ECO-4601 in humans, the pharmaceutical potential of ECO-4601 in specific cancer indications, the pharmaceutical potential of the 59 New Chemical Entities (NCEs) discovered by the DECIPHER® platform and the potential of the DECIPHER® platform to discover additional NCEs involve risk and uncertainties. Actual events could differ materially from those projected here and depend on a number of factors, including scientific uncertainties relating to the correlation between preclinical animal data and human clinical data, uncertainties related to the regulatory process for drug development, the success and timely completion of profiling of NCEs for preclinical development, and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements. A more complete discussion of the risks and uncertainties facing the Company appears in Ecopia's 2005 Annual Report.

Contact Information